Original article

Clinical study of leukocyte-to-platelet ratio in early evaluating prognosis of sepsis

Expand
  • Department of Emergency, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2021-10-13

  Online published: 2022-08-09

Abstract

Objective To investigate the clinical value of white blood cell-to-platelet (WBC/PLT) ratio and related factors in early prognosis evaluation of sepsis. Methods The clinical data of 150 patients diagnosed with sepsis admitted to the emergency intensive care unit (EICU) in Ruijin Hospital, Shanghai Jiao Tong University School of Medicine from June 2018 to June 2020 were prospectively analyzed. According to survival or death, the patients were divided into survival group(n=126) and death group(n=24). The difference of WBC/PLT and clinical and biochemical indexes between two groups in 24 h after onset of sepsis were compared, and the Pearson correlation was used to analyze the correlation between WBC/PLT ratio and risk factors in the patients with sepsis. The Cox regression model was used to evaluate the clinical predictive value of various factors on mortality, and the receiver operating characteristic(ROC) curve was applied to analyze the predictive effect of WBC/PLT ratio on prognosis in the patients with sepsis. Result There was no significant difference in age, gender, infection type and constituent ratio of underlying diseases between the survival or death groups (P>0.05). The proportion of septic shock patients, receiving vasoactive medicines, mechanical ventilation and blood purification in the death group were significantly higher than those in the survival group(P<0.05). The levels of procalcitonin (PCT), urea nitrogen, aspartate aminotransferase (AST), prothrombin time (PT), fibrinogen degradation product (FDP), D-dimer, pro-brain natriuretic peptide(pro-BNP)and sequential organ failure assessment(SOFA) scores in the death group were significantly higher than those in the survival group. The ratio of WBC/PLT in death group (0.56±1.27) was significantly higher than that in survival group(0.15±0.42)(P<0.05). The Pearson correlation analysis showed that the ratio of WBC/PLT was positively correlated with C-reaction protein(CRP), PCT, urea nitrogen, creatinine, pro-BNP, FDP, and D-dimer(P<0.05). The Cox regression model analysis presented that high WBC/PLT ratio, high urea nitrogen level and high SOFA score were independent risk factors for prognosis in the patients with sepsis (P<0.05). The area under ROC curve of WBC/PLT ratio was 0.643(95% CI: 0.516-0.770, P=0.026), and an optimal cut-off value was 0.186, with sensitivity of 37.5% and specificity of 91.3%. Conclusions The WBC/PLT ratio shows high specificity in the prognosis evaluation of sepsis, which can predict the prognosis of patients early, and is worth to be used in clinical practice.

Cite this article

CHEN Min, CHE Zaiqian, CHEN Ying, MA Li, ZHAO Bing, ZHOU Weijun, MAO Enqiang, CHEN Erzhen . Clinical study of leukocyte-to-platelet ratio in early evaluating prognosis of sepsis[J]. Journal of Internal Medicine Concepts & Practice, 2022 , 17(03) : 208 -213 . DOI: 10.16138/j.1673-6087.2022.03.007

References

[1] Weng L, Zeng XY, Yin P, et al. Sepsis-related mortality in China: a descriptive analysis[J]. Intensive Care Med, 2018, 44(7): 1071-1080.
[2] Xie J, Wang H, Kang Y, et al. The epidemiology of sepsis in Chinese ICUs[J]. Crit Care Med, 2020, 48(3): e209-e218.
[3] Kaukonen KM, Bailey M, Suzuki S, et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012[J]. JAMA, 2014, 311(13): 1308-1316.
[4] Rhodes A, Phillips G, Beale R, et al. The surviving sepsis campaign bundles and outcome: results from the International Multicentre Prevalence Study on Sepsis (the IMPreSS study)[J]. Intensive Care Med, 2015, 41(9): 1620-1628.
[5] Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations[J]. Am J Respir Crit Care Med, 2016, 193(3): 259-272.
[6] Larsen FF, Petersen JA. Novel biomarkers for sepsis: a narrative review[J]. Eur J Intern Med, 2017, 45: 46-50.
[7] Giannakopoulos K, Hoffmann U, Ansari U, et al. The use of biomarkers in sepsis[J]. Curr Pharm Biotechnol, 2017, 18(6): 499-507.
[8] Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)[J]. JAMA, 2016, 315(8): 762-774.
[9] Churpek MM, Snyder A, Han X, et al. Quick sepsis-related organ failure assessment, systemic inflammatory response syndrome, and early warning scores for detecting clinical deterioration in infected patients outside the intensive care unit[J]. Am J Respir Crit Care Med, 2017, 195(7): 906-911.
[10] Martin JB, Badeaux JE. Interpreting laboratory tests in infection: making sense of biomarkers in sepsis and systemic inflammatory response syndrome for intensive care unit patients[J]. Crit Care Nurs Clin North Am, 2017, 29(1): 119-130.
[11] Scarlatescu E, Tomescu D, Arama SS. Anticoagulant therapy in sepsis[J]. J Crit Care Med (Targu Mures), 2017, 3(2): 63-69.
[12] Simmons J, Pittet JF. The coagulopathy of acute sepsis[J]. Curr Opin Anaesthesiol, 2015, 28(2): 227-236.
[13] Yao YM, Luan YY, Zhang QH, et al. Pathophysiological aspects of sepsis[J]. Methods Mol Biol, 2015, 1237: 5-15.
[14] Schnoor M, García Ponce A, Vadillo E, et al. Actin dynamics in the regulation of endothelial barrier functions and neutrophil recruitment during endotoxemia and sepsis[J]. Cell Mol Life Sci, 2017, 74(11): 1985-1997.
[15] Alves-Filho JC, de Freitas A, Spiller F, et al. The role of neutrophils in severe sepsis[J]. Shock, 2008, 30 Suppl 1: 3-9.
[16] Shen XF, Cao K, Jiang JP, et al. Neutrophil dysregulation during sepsis: an overview and update[J]. J Cell Mol Med, 2017, 21(9): 1687-1697.
[17] Venkata C, Kashyap R, Farmer JC, et al. Thrombocytopenia in adult patients with sepsis: incidence, risk factors, and its association with clinical outcome[J]. J Intensive Care, 2013, 1(1): 9.
[18] Woth G, Varga A, Ghosh S, et al. Platelet aggregation in severe sepsis[J]. J Thromb Thrombolysis, 2011, 31(1): 6-12.
[19] Vardon-Bounes F, Ruiz S, Gratacap MP, et al. Platelets are critical key players in sepsis[J]. Int J Mol Sci, 2019, 20(14): 3494.
[20] Iba T, Levy JH. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis[J]. J Thromb Haemost, 2018, 16(2): 231-241.
[21] de Stoppelaar SF, van 't Veer C, van der Poll T. The role of platelets in sepsis[J]. Thromb Haemost, 2014, 112(4): 666-677.
[22] Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)[J]. JAMA, 2016, 315(8): 801-810.
[23] American College of Chest Physicians/Society of Critical Care Medicine. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis[J]. Crit Care Med, 1992. 20(6): 864-874.
[24] Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference[J]. Intensive Care Med, 2003, 29(4): 530-538.
[25] Kaukonen KM, Bailey M, Pilcher D, et al. Systemic inflammatory response syndrome criteria in defining severe sepsis[J]. N Engl J Med, 2015, 372(17): 1629-1638.
[26] McDonald B, Dunbar M. Platelets and intravascular immunity: guardians of the vascular space during bloodstream infections and sepsis[J]. Front Immunol, 2019, 10: 2400.
[27] Thiery-Antier N, Binquet C, Vinault S, et al. Is thrombocytopenia an early prognostic marker in septic shock?[J]. Crit Care Med, 2016, 44(4): 764-772.
[28] Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial[J]. Lancet, 2010, 375(9713): 463-474.
[29] Thomas MR, Storey RF. The role of platelets in inflammation[J]. Thromb Haemost, 2015, 114(3): 449-458.
[30] Zhang W, Zheng Y, Feng X, et al. Systemic inflammatory response syndrome in Sepsis-3[J]. BMC Infect Dis, 2019, 19(1): 139.
[31] Donnelly JP, Safford MM, Shapiro NI, et al. Application of the Third International Consensus Definitions for Sepsis (Sepsis-3) Classification[J]. Lancet Infect Dis, 2017, 17(6): 661-670.
Outlines

/